Literature DB >> 22843332

Differential routes of carboplatin administration influence lymphocyte apoptosis in retroperitoneal lymph nodes.

Yong-Wen Huang1, Zheng Zeng, Su Li, Ji-Hong Liu.   

Abstract

We aimed to investigate carboplatin distribution in retroperitoneal lymph nodes and its effect on lymphocyte apoptosis following intravenous (IV), intra-arterial (IA), and retroperitoneal (RP) administration. Sixty-three healthy female canines were randomly assigned as IV, IA, or RP administration of carboplatin. At 0.5, 1, 2, 4, 8, 24, and 72 h after carboplatin treatment, retroperitoneal lymph nodes (n = 6 at each time point) were collected and high-performance liquid chromatography was employed to measure the carboplatin content. The differences in carboplatin pharmacokinetics of the three administration routes were compared. Terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) was carried out to measure the lymphocyte apoptosis of the retroperitoneal lymphocytes. The peak concentration of carboplatin in plasma following IV administration was the highest among all approaches; as to the peak time, RP administration was longer than the other two administrations. Concentration for carboplatin in the retroperitoneal lymph node was highest following IA administration at early time points, but at higher time points, concentration was significantly higher following RP administration. Penetration of carboplatin into the retroperitoneal space was higher following RP administration. Following RP administration, the level of apoptotic lymphocytes in the retroperitoneal lymph nodes was significantly greater than either IV or IA. Following RP administration of carboplatin, the concentration, area under the curve of carboplatin and the number of apoptotic lymphocytes were significantly higher than those following IV and IA administration. This suggests that RP administration of carboplatin is beneficial for the treatment of retroperitoneal lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22843332     DOI: 10.1007/s13277-012-0464-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  13 in total

1.  Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma? A DEGOG* Study.

Authors:  Ugur Saygili; Serkan Guclu; Turhan Uslu; Oktay Erten; Sevgi Ture; Namik Demir
Journal:  J Surg Oncol       Date:  2002-11       Impact factor: 3.454

2.  Ovarian cancer patients with "node-positive-only" Stage IIIC disease have a more favorable outcome than Stage IIIA/B.

Authors:  G Ferrandina; G Scambia; F Legge; M Petrillo; V Salutari
Journal:  Gynecol Oncol       Date:  2007-07-05       Impact factor: 5.482

3.  [Clinical study of platinum accumulation in gastric cancer after preoperative intra-arterial injection of cisplatin].

Authors:  A Itoh; H Taniguchi; T Daidoh; N Tsukuda; Y Shioaki; K Seiki; T Yokota; T Yamane; T Yamaguchi; K Sawai
Journal:  Gan To Kagaku Ryoho       Date:  1989-08

4.  Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients?

Authors:  S Suzuki; H Kajiyama; K Shibata; K Ino; A Nawa; K Sakakibara; K Matsuzawa; A Takeda; Y Kinoshita; M Kawai; T Nagasaka; F Kikkawa
Journal:  Ann Oncol       Date:  2008-03-19       Impact factor: 32.976

5.  Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications.

Authors:  Philippe Morice; Franklin Joulie; Sophie Camatte; David Atallah; Roman Rouzier; Patricia Pautier; Christophe Pomel; Catherine Lhommé; Pierre Duvillard; Damienne Castaigne
Journal:  J Am Coll Surg       Date:  2003-08       Impact factor: 6.113

Review 6.  Intraperitoneal chemotherapy in the management of ovarian cancer.

Authors:  M Markman; B Reichman; T Hakes; J Curtin; W Jones; J L Lewis; R Barakat; S Rubin; B Mychalczak; P Saigo
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

7.  Lymph node metastasis in a gynecologic malignancy.

Authors:  Toshiharu Kamura; Jin Dong Jeon
Journal:  Yonsei Med J       Date:  2002-12       Impact factor: 2.759

Review 8.  Inhibition of transcription by platinum antitumor compounds.

Authors:  Ryan C Todd; Stephen J Lippard
Journal:  Metallomics       Date:  2009       Impact factor: 4.526

9.  Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy.

Authors:  P Morice; F Joulie; A Rey; D Atallah; S Camatte; P Pautier; A Thoury; C Lhommé; P Duvillard; D Castaigne
Journal:  Eur J Gynaecol Oncol       Date:  2004       Impact factor: 0.196

10.  Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin.

Authors:  Maurie Markman
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.